{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:04:40Z","timestamp":1774890280508,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.plefa.2012.04.012","type":"journal-article","created":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T17:15:52Z","timestamp":1341076552000},"page":"17-24","source":"Crossref","is-referenced-by-count":12,"title":["Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6)"],"prefix":"10.1016","volume":"87","author":[{"given":"Shahrzad Soleymani","family":"Fard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood Jeddi","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali M.","family":"Ardekani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2012.04.012_bib1","first-page":"117","article-title":"Acute lymphoblastic leukemia: a model for the pharmacogenomics of cancer therapy","volume":"6","author":"Cheok","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.plefa.2012.04.012_bib2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapsed and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.plefa.2012.04.012_bib3","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/sj.onc.1205328","article-title":"Differentiation induction as a treatment for hematologic malignancies","volume":"21","author":"Miller","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.plefa.2012.04.012_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.leukres.2009.08.021","article-title":"Histone deacetylase inhibitors: a new perspective for the treatment of leukemia","volume":"34","author":"Abujamra","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbamcr.2004.10.016","article-title":"Prostaglandin D2 and J2 induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species","volume":"1743","author":"Chen","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.plefa.2012.04.012_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.neuint.2004.02.005","article-title":"Prostaglandin E2 induced caspase-dependent apoptosis possibly through activation of EP2 receptors in cultured hippocampal neurons","volume":"45","author":"Takadera","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.plefa.2012.04.012_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0090-6980(93)90123-O","article-title":"Prostaglandin-induced apoptosis of ovarian surface epithelial cells","volume":"45","author":"Ackerman","year":"1993","journal-title":"Prostaglandins"},{"issue":"3","key":"10.1016\/j.plefa.2012.04.012_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BIBU.0000030141.78751.90","article-title":"Apoptosis in P388 leukemia cells induced by specific inhibitors of 5- and 12-lipoxygenase and the product of cyclooxygenase, prostaglandin E2","volume":"31","author":"Grichenko","year":"2004","journal-title":"Biol. Bull."},{"key":"10.1016\/j.plefa.2012.04.012_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-6980(98)00073-2","article-title":"Prostaglandin E2 regulates vitamin D receptor expression, vitamin D24-hydroxylase activity and cell proliferation in an adherent human myeloid leukemia cell line (Ad-HL60)","volume":"57","author":"Smith","year":"1999","journal-title":"Prostaglandins other Lipid Mediators"},{"issue":"2","key":"10.1016\/j.plefa.2012.04.012_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157488706776876490","article-title":"Review: recent clinical trials in epigenetic therapy","volume":"1","author":"Oki","year":"2006","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.plefa.2012.04.012_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.20372","article-title":"Histone deacetylase inhibitors: understanding a new wave of anti-cancer agents","volume":"112","author":"Garea-Villar","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.plefa.2012.04.012_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","article-title":"Histone deacetylase inhibitors: mechanisms o f cell death and promise in combination cancer therapy","volume":"269","author":"Carew","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.plefa.2012.04.012_bib13","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2174\/0929867033456602","article-title":"From discovery to the coming generation of histone deacetylase inhibitors","volume":"22","author":"Yoshida","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.plefa.2012.04.012_bib14","first-page":"605","article-title":"Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells","volume":"22","author":"Park","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.plefa.2012.04.012_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.plefa.2012.04.012_bib16","first-page":"68","article-title":"The role of DNA methylation in mammalian epigenetics","volume":"293","author":"Jones","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.plefa.2012.04.012_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1568011033482440","article-title":"The interaction of histone deacetylase inhibitor and DNA methyltransferase inhibitors in the treatment of human cancer cells","volume":"3","author":"Zhu","year":"2003","journal-title":"Curr. Med. Chem. Anti-Cancer Agents"},{"key":"10.1016\/j.plefa.2012.04.012_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-642-59696-4_9","article-title":"Methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobin opathies: clinical results and possible mechanisms of action","volume":"249","author":"Lubbert","year":"2000","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.plefa.2012.04.012_bib19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low-dose 5-aza-2deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.plefa.2012.04.012_bib20","first-page":"1442","article-title":"Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies","volume":"4","author":"Lyons","year":"2003","journal-title":"Curr. Opinion Invest. Drugs"},{"key":"10.1016\/j.plefa.2012.04.012_bib21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.plefa.2012.04.012_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0145-2126(02)00162-5","article-title":"(4 Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL)","volume":"27","author":"Faderl","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-007-9485-1","article-title":"Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells","volume":"87","author":"Das","year":"2008","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.plefa.2012.04.012_bib24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.V1261188","article-title":"Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells","volume":"12","author":"Wagner","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.plefa.2012.04.012_bib25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2141.2005.05395.x","article-title":"Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukemia","volume":"128","author":"Matsui","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.plefa.2012.04.012_bib26","first-page":"275","article-title":"The role of growth factors in the activity of pharmacological differentiation agents","volume":"13","author":"Matsui","year":"2002","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.plefa.2012.04.012_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0163-7258(01)00132-2","article-title":"Differentiation therapy of human cancer: basic science and clinical applications","volume":"90","author":"Leszczyniecka","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.plefa.2012.04.012_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V100.2.640","article-title":"Immature CD34+CD19 progenitor\/stem cells in TEL\/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal","volume":"100","author":"Hot\ufb01lder","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.plefa.2012.04.012_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nm1253","article-title":"Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia","volume":"11","author":"Castor","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.plefa.2012.04.012_bib30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19 cells","volume":"65","author":"Hot\ufb01lder","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib31","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.159.7.3278","article-title":"Regulation of B lymphocyte development and activation by the CD19\/CD21\/ CD81\/Leu 13 complex requires the cytoplasmic domain of CD19","volume":"159","author":"Sato","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.plefa.2012.04.012_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1385\/IR:22:2-3:281","article-title":"CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive ampli\ufb01cation","volume":"22","author":"Fujimoto","year":"2000","journal-title":"Immunol. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/1521-4141(200104)31:4<1261::AID-IMMU1261>3.0.CO;2-H","article-title":"Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice","volume":"31","author":"Donis-Hernandez","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.plefa.2012.04.012_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/sj.leu.2404823","article-title":"Induction of acute lymphocytic leukemia differentiation by maintenance therapy","volume":"21","author":"Lin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.plefa.2012.04.012_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yexmp.2006.02.004","article-title":"Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells","volume":"82","author":"Joo Woo","year":"2007","journal-title":"Exp. Mol. Pathol."},{"issue":"5","key":"10.1016\/j.plefa.2012.04.012_bib36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejca.2008.01.023","article-title":"Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukemia cell lines: role of annexin A1","volume":"44","author":"Petrella","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.plefa.2012.04.012_bib37","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1182\/blood-2007-10-117762","article-title":"The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells","volume":"111","author":"Scuto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.plefa.2012.04.012_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2006.08.010","article-title":"The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines","volume":"549","author":"Savickiene","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.plefa.2012.04.012_bib39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.phrs.2006.08.003","article-title":"NF-\u03baB signaling pathway is involved in growth inhibition, G2\/M arrest and apoptosis induced by trichostatin A in human tongue carcinoma cells","volume":"54","author":"Yao","year":"2006","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jss.2006.12.555","article-title":"The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells","volume":"142","author":"Platta","year":"2007","journal-title":"J. Surg. Res."},{"issue":"15","key":"10.1016\/j.plefa.2012.04.012_bib41","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.plefa.2012.04.012_bib42","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.plefa.2012.04.012_bib43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.plefa.2012.04.012_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.21552","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia","volume":"106","author":"Kuendgen","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.plefa.2012.04.012_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0145-2126(93)90045-M","article-title":"Cytotoxic activity and mechanism of action of 5-aza-2-deoxycytidine in human CML cells","volume":"17","author":"Limonta","year":"1993","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.plefa.2012.04.012_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0145-2126(84)90141-3","article-title":"5-Aza-2-deoxycytidine therapy in patients with acute leukemia inhibits and methylation","volume":"8","author":"Momparler","year":"1984","journal-title":"Leuk. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0145-2126(81)90116-8","article-title":"Phase I study on 5-aza-2-deoxycytidine in children with acute leukemia","volume":"6","author":"Rivard","year":"1981","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.plefa.2012.04.012_bib48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2010.04.014","article-title":"3-Deazauridine enhances the antileukemic action of 5-aza-2-deoxycytidine and targets drug-resistance due to de\ufb01ciency in deoxycytidine kinase","volume":"35","author":"Raynal","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.plefa.2012.04.012_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-5793(86)80876-6","article-title":"1,25-Dihydroxyvitamin D enhances prostaglandin E production by monocytes. (A mechanism which partially accounts for the antiproliferative effect of 1,25(OH),D on lymphocytes)","volume":"205","author":"Koren","year":"1986","journal-title":"FEBS Lett."},{"key":"10.1016\/j.plefa.2012.04.012_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(08)61384-4","article-title":"Differentiation-related changes in the cell cycle traverse","volume":"189","author":"Studzinski","year":"1999","journal-title":"Int. Rev. Cytol."},{"issue":"2","key":"10.1016\/j.plefa.2012.04.012_bib52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0006-291X(86)80219-4","article-title":"Growth inhibitory effects of 5-aza-2-deoxycytidine in HL-60 promelocytic leukemia cells resistant to differentiation induction","volume":"141","author":"Levva","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.plefa.2012.04.012_bib53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11596-006-0511-x","article-title":"Effects of trichostatin A on HDAC8 expression, proliferation and cell cycle of Molt-4 cells","volume":"26","author":"Jing","year":"2006","journal-title":"J. Huazhong Univ. Sci. Technol."},{"key":"10.1016\/j.plefa.2012.04.012_bib54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.leukres.2007.05.026","article-title":"Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor KB","volume":"32","author":"Nishioka","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.plefa.2012.04.012_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0304-3835(02)00347-6","article-title":"Apoptosis sensitivity is not correlated with sensitivity to proliferation inhibition by the histone deacetylase inhibitors butyrate and TSA","volume":"188","author":"Ga\u00b4l\ufb01","year":"2002","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.plefa.2012.04.012_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/jpet.104.074195","article-title":"5-AZA-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms","volume":"312","author":"Schneider-Stock","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.plefa.2012.04.012_bib57","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/1535-7163.MCT-05-0218","article-title":"The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells","volume":"4","author":"His","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.plefa.2012.04.012_bib58","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10620-007-9787-3","article-title":"The anti-cancer effect of COX-2 inhibitors on gastric cancer cells","volume":"52","author":"Cho","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.plefa.2012.04.012_bib59","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/1535-7163.MCT-05-0218","article-title":"The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells","volume":"4","author":"His","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.plefa.2012.04.012_bib60","first-page":"53","article-title":"Flow cytometric analysis of 4-HPR-induced apoptosis and cell cycle arrest in acute myelocytic leukemia cell line (NB-4)","volume":"2","author":"Soleymanifard","year":"2010","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"4","key":"10.1016\/j.plefa.2012.04.012_bib61","first-page":"177","article-title":"Bryostatin-1, fenretinide and 1\u03b1,25(OH)2D3 induce growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6)","volume":"3","author":"Ardekani","year":"2011","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"10.1016\/j.plefa.2012.04.012_bib62","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2004-03-0901","article-title":"Characterization of acute lymphoblastic leukemia progenitor cells","volume":"104","author":"Cox","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.plefa.2012.04.012_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(00)00228-3","article-title":"Immunophenotyping of leukemia","volume":"243","author":"Campana","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.plefa.2012.04.012_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexmp.2006.06.006","article-title":"The immunophenotype of pre-TALL\/LBL revisited","volume":"81","author":"Lewis","year":"2006","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.plefa.2012.04.012_bib65","first-page":"36","article-title":"Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia","volume":"8","author":"Popov","year":"2010","journal-title":"Klin. Lab. Diagn."},{"issue":"6","key":"10.1016\/j.plefa.2012.04.012_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4149\/neo_2009_06_508","article-title":"Immunophenotyping parameters as prognostic factors in T-acute leukemia patients","volume":"56","author":"Babusikova","year":"2009","journal-title":"Neoplasma"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327812000701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327812000701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:39:41Z","timestamp":1687567181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327812000701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0952327812000701"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2012.04.012","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}